Temporarily Closed. New orders are paused while we resolve an unforeseen operational issue. Existing orders will still be fulfilled.

MOTS-c

Accelerating

MOTS-c appears in 283 indexed publications going back to 2015, including 61 in the past twelve months. 4 registered trials appear on ClinicalTrials.gov.

283
Indexed publications
61
Past 12 months, against 45 the year before
4
Registered clinical trials
3,472
Monthly readers on Wikipedia, down 2%
Research Activity

Publication history

How much work has been indexed each year, from Europe PMC. Momentum is measured over a trailing twelve months rather than calendar years, so a partial current year never reads as a decline.

20152026

Publications per year. The final bar is the current year, still in progress.

Indexed publications per year
20154
20163
20173
201813
201922
202014
202131
202222
202335
202432
202546
202656
Public Attention

Who is looking it up

Monthly readers of the MOTS-c article on English Wikipedia. An independent measure of curiosity, which often moves quite differently from the evidence.

2025-102026-09
Clinical Trials

The registered pipeline

Early Phase 1
0
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0

Phase distribution across the most recently updated registered trials.

References

Most recent work

The newest indexed records mentioning MOTS-c, listed by publication date. Titles are shown as published and link to their source. Inclusion here is a record of what exists, not a judgement of what it shows.

  1. 2026-08-14·Bioactive materials

    Mitochondria-derived peptide hydrogel augments mitochondrial transplantation for promoting cardiac repair via macrophage metabolic reprogramming

    Li H, Zhang Y, Jian Y et al.

  2. 2026-05-13·International urology and nephrology

    MOTS-c is associated with oxidative stress and arterial stiffness in peritoneal dialysis patients: a pilot study

    Musolino M, Roumeliotis A, Roumeliotis S et al.

  3. 2026-10-23·Biochemical pharmacology

    Mots-c attenuates diabetic nephropathy by downregulating LARS1 to promote lipophagy and suppress tubular senescence

    Wang J, Luo S, Han Y et al.

  4. 2026-10-19·Reproduction & fertility

    The Mitochondrial-Derived Peptide MOTS-c Improves Bioenergetics in Aging-Associated Granulosa Cells and Oocytes

    Tsui KH, Cheng SH, Lin LT et al.

  5. 2026-10-11·Tissue & cell

    Mitochondrial-derived peptides in female reproduction: Emerging regulators of oocyte competence and novel therapeutic opportunities for infertility

    Rostami Z, Galeshi M, Mosapour A. et al.

  6. 2026-08-25·Physiology international

    Mitochondrial-derived peptides (MDPs) activated by physical exercise as therapeutic targets for metabolic disorders: A systematic review

    Ayubi N, Wibawa JC, Kurnaz M et al.

  7. 2026-08-23·European journal of pharmacology

    MOTS-c in sepsis-induced cardiomyopathy: Mechanisms and translational potential

    Zhao Z, Chen W, Zheng X et al.

  8. 2026-06-02·Autophagy

    MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation

    Shi J, Wu Y, Liu X et al.

In the Catalogue

MOTS-c available from Polaris Research

Supplied as research materials for laboratory use. Free express delivery Australia wide.

Sources

Publication data from Europe PMC. Clinical trial data from ClinicalTrials.gov, U.S. National Library of Medicine. Public attention from Wikimedia pageview data. Evidence grades from reptides.co. We report counts and dates from these sources and link every record to its origin, we do not summarise findings. Last synced 2026-10-25.